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ABSTRACT 
Carboxylesterases (CES) catalyze both hydrolytic and synthetic reactions and play 
important roles in drug metabolism and lipid mobilization. Many factors such as age 
and dietary supplements have been shown to regulate the CES expression. The 
expression of CES1 shows the developmental regulation and is highly induced by 
antioxidants. The goals of this project were to determine whether CES2, like CES1, is 
developmentally regulated and to investigate how antioxidants induced the expression 
of CES1 at the molecular level. 
The ontogenic studies showed the mRNA levels of CES2 exhibited a postnatal surge 
(1-31 days versus 35-70 days) in both liver and duodenum. The levels of CES2 
protein increased with age as well. However, individual donor multi-sampling CES2 
expression studies showed the significant correlation between the duodenum and 
jejunum but insignificant correlation between the liver and duodenum. Moreover, the 
metabolic enzyme cytochrome P450 3A4 (CYP3A4) which share substrates with 
CES2 in many case have a comparable age related expression pattern but the mRNA 
level of CYP3A4 in the duodenum showed otherwise. 
The mechanistic studies on CES1 induction used the dissected regulatory sequence of 
the CES1A1 gene to locate the element supporting the transactivation. A novel 
element was identified and designated as sensitizing/antioxidant response element 
(S/ARE). Comparing with the known antioxidant element ARE4, the novel element 
supported whereas the ARE4 element repressed the transactivation. The 
Electrophoretic mobility shift assay and Chromatin immunoprecipitation experiments 
demonstrated that the S/ARE element serves as a major site to interact with the 
CES1A1 gene and both elements were bound by nuclear factor-E2 related factor-2 
(Nrf2). 
In conclusion, CES2 and CYP3A4 are expressed under developmental regulation and 
whether the regulation occurs in a gene-dependent or an organ-dependent manner. 
Both positive and negative Nrf2 response elements exist even within the same gene. 
The identification of ARE4 supported Nrf2 repression, given the fact that Nrf2 is 
generally considered to confer transactivation activity. 
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CHAPTER 1 
 
INTRODUCTION 
 
CARBOXYLESTERASES 
1. Overview of carboxylesterases 
Carboxylesterases (CES, E.C.3.1.1.1) constitute a large class of enzymes that play 
important roles in drug metabolism and lipid mobilization [1-4]. These enzymes not 
only catalyze hydrolytic and synthetic reactions but also interact with other proteins. 
Their primary function is hydrolysis. The foreign carboxylic acid ester, amides and 
thioesters compounds are hydrolyzed into two components by carboxylesterases ( 
Figure 1.1). Hydrolysis of compounds usually causes severe changes in the electronic 
charge and the structure and completely affects the pharmacokinetic and 
pharmacodynamics characteristics of compounds [5-9]. In addition, numerous 
endogenous substrates such as triglycerides and cholesterol esters also are hydrolyzed 
by carboxylesterases [4-7] and relocate to different organelles through the 
re-esterification – hydrolysis cycle [10].  
Multiple forms of carboxylesterases are expressed in all mammalian species. Based 
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on the current approach, there are six families of all mammalian carboxylesterases, 
CES1, CES2, CES3, CES4, CES5, and CES6 and the members of each family share 
at least 60% of the sequence identity [6]. The two major families of the 
carboxylesterases are CES1 and CES2. The largest number of carboxylesterases 
belong to CES1 and eight subfamilies have been assigned [6]. The CES1 of humans, 
rabbits and monkeys belong to the CES1A subfamily and the CES1 of the mice, rats 
and hamsters are covered by CES1B. The CES1 of pigs, dogs and cats are members 
of CES1C [11-18]. Almost all CES1 subfamilies are expressed mainly in the liver 
expect CES1G [16, 19]. In contrast, CES2 are expressed mainly in the intestines, 
especially in the small intestines. The CES2 family contains human (CES2A1), rat 
(CES2A10), mice (CES2A6) and rabbit isoenzymes (Table 1.1) [20-27]. 
There are seven distinct carboxylesterase genes found in the human genome, CES1A1, 
CES1A2, CES1A3, CES2, CES3, CES5 and CES6 respectively [5, 28, 29]. With 
39-44% sequences identity [28, 29], the major differences between the CES1A1 and 
CES1A2 genes are in the promoters and leader sequence regions. Their functional 
mature proteins have four different amino acids in the signal peptide. The CES1A3 
gene is considered a pseudo gene because of a premature stop codon. Humans can 
only express either CES1A2 or CES1A3. Unlike the CES1 family, there is only one 
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member from each CES2, CES3, CES5 and CES6 expressed in humans [5]. The 
CES1 is found as a trimer or hexamer and the CES2 and CES3 exist as a monomer. 
The CES2 gene is expressed at different levels of mRNA and in proteins in different 
tissues through their transcription by three alternative promoters and two in-frame 
ATG’s [30]. CES3 has 40% identical sequences compared with CES1 and CES2. 
However, it shows very low activity with commonly used substrates [31]. CES5 and 
CES6 have more glycosylation sites than others CESs and both of them are the 
secretory protein. The activities of CES5 and CES6 remain unclear.  
The human liver expresses higher level of carboxylesterases than other organs and 
shows the highest overall carboxylesterase activity. In the liver, larynx, esophagus and 
lungs, CES1 has been found. CES2 is mainly found in the gastrointestinal track, the 
kidney and the liver (Table 1.1). CES3 shows a low level in the trachea, intestine and 
placenta [32]. In contrast, the rodents contain abundant serum carboxylesterases and 
none of common human carboxylesterases (CES1, CES2 and CES3) have been found 
in normal serum [33]. 
The substrate specificity of carboxylesterases is considered to be ample and 
overlapping. The substrate specificity of two major human carboxylesterases 
isozymes (CES1 and CES2) have been characterized in the past decade [3, 5, 6, 34]. 
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The substrates of CES1 generally have a small alcohol moiety and a large acyl moiety. 
In contrast, substrates of CES2 have a large alcohol moiety and a small acyl moiety 
(Figure 1.4). For example, CES1 rather than CES2 rapidly hydrolyzes 
methylphenidate since the acyl moiety (methylphenidate carboxylate) is much larger 
than the alcohol moiety (methanol) [7]. In the antiplatelet agent, prasugrel, the acyl 
moiety is much smaller than the alcohol moiety, so it is mostly hydrolyzed by CES2 
[35]. If the compound has more than one ester bonds, it also fit this alcohol/acid size - 
based preference. For example, cocaine contains two ester bonds and can be 
hydrolyzed to ecgonine, methanol, and benzoic acid. CES1 breaks the ester bond 
which connects the largest acid (ecgonine) and the small alcohol (methanol) and 
CES2 hydrolyzes benzoate – ecgoninyl ester (Figure 1.). However, there are some 
exceptions to this alcohol/acid size based rule. 
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Figure 1.1 Representative drugs chemical structures which are metabolized by 
carboxylesterases. The arrows show chemical bonds which are hydrolyzed by 
carboxylesterases. 
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1 and CES2 in mammals [32]. 
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Figure 1.2 Examples of substrate specificity of human carboxylesterases CES1 and 
CES2. The arrows indicate bonds hydrolyzed by carboxylesterases and the boxes 
show the acid moieties of compounds. 
Prasugrel
Methylphenidate 
 
 
 
Cocaine 
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2. Ontogenic Expression 
The expression of carboxylesterases shows developmental regulation in humans and 
rodents. During developmental stages, the human hydrolytic capacity shows an early 
surge in the neonatal stage and remains high through adolescence [36, 37]. CES1 
mRNA has a postnatal surge in first two months [36]. In addition, adult humans 
express significantly higher carboxylesterase than children and children express much 
higher CES than fetuses. Large inter-individual variability (mRNA (430-fold), protein 
(100-fold) and hydrolytic activity (127-fold)) are found in the child and fetal groups 
but not in the adult group. That indicates the pharmacokinetics parameters of ester 
drugs in children may vary widely and the dosage of ester drugs needs to be carefully 
adjusted in children. [37] 
CES1 expression shows a surge during post-neonatal stage. The mRNA and protein of 
the CES1 increases 4–7-fold in the hydrolysis and the expression analyses between 
the 1–31days and 35–70days groups. However, the other 3 pediatric groups (35–70, 
89–119, 123–198) show similar levels. The 1–31d group and other 3 pediatric groups 
show only 10% and 50% of the expression level of adult group [37]. Based on these 
results, dosing regimens of ester drugs should be extra carefully monitored to prevent 
the possible side effects [37]. 
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For the rat, there are no hydrolases A or B. Two major rat carboxylesterases are 
expressed in one to two weeks old rats [38]. Their intrinsic hydrolytic clearance is 
only 3% of adults. The clearance of four weeks old rats is less than half that of adults 
rats [39]. Moreover, animals are extremely sensitive to pesticides such as 
organophosphates and pyrethroids. Carboxylesterases detoxify them through 
hydrolysis or a scavenging mechanism. Interestingly, the inducibility of 
carboxylesterases shows an inverse relationship with age. The mRNA, protein and 
catalytic levels of six major carboxylesterases in neonatal mice (10 days of age) show 
a greater extent of induction than the adult mice after phenobarbital treatment [40]. 
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3. Xenobiotic regulation 
The catalytic activity of carboxylesterases can be manipulated by activators or 
inhibitors[57]. Pinacolone has been observed to increase in vitro and in vivo activities 
of carboxylesterases [58]. Acetone, a commonly used solvent, also shows the ability 
to enhance enzyme activity by increasing the accessibility of the substrate [58]. 
Chemicals induce or suppress the expression of carboxylesterase through different 
signaling pathways. There are various regulation pathways of induction which may 
lead to the differences. The inducers of carboxylesterases expression show differences 
in species in induction. Some factors which regulate the expression show the species 
differences and some do not. The glucocorticoid drug, dexamethasone, increases the 
expression of human carboxylesterases [41] but decreases the various rat 
carboxylesterases even as low as the nanomolar (nM) level [42]. On the other hand, 
phenobarbital, the most widely used anticonvulsant, induces the expression of 
carboxylesterases across species [41, 43] through the constitutive androstane receptor 
(CAR) and pregnane X receptor pathways (PXR) [44, 45]. Guggulsterone upregulates 
the expression of human carboxylesterases through transcription factor, nuclear factor 
(erythroid-derived 2)-like 2 (Nrf2) [46-48]. Moreover, 3-methylcholaanthrene is a 
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ligand of the aryl hydrocarbon receptor (AhR) and only increases the enzyme in rats 
[49]. 
Compounds with similar structures, may not have the same regulatory effect. Both 
dexamethasone and pregnenolone 16 α - carbonitrile (PCN) contain 
cyclopenta[a]phenanthrene as a basic structure. However, dexamethasone suppresses 
carboxylesterases expression and PCN moderately induce the expression [19, 42]. 
Some chemicals have similar ability to induce the cytochrome P450 (CYP) enzymes 
but may have the reverse effect in regulating carboxylesterases. For example, 
isoniazid and streptozotocin, inducers of CYP2E1, show the opposite effect of 
carboxylesterases. Streptozotocin is a weak inducer and isoniazid strongly suppresses 
the expression [19, 50]. 3 – methylcholanthrene and β - naphthoflavone induce 
carboxylesterases but have the opposite effect of CYP 1A. The first compound 
induces the hydrolase S but the second one suppresses it [19, 50]. 
Antioxidants and sensitizers are two types of chemicals also show the induction of 
CES. The induction of this carboxylesterase by antioxidants is mediated by Nrf2 [22]. 
This transcription factor recognizes the antioxidant response element (ARE) and 
confers transactivation [23]. RNA interference against Nrf2 cancels CES1 induction 
by antioxidants [22]. The majority of skin sensitizers, on the other hand, are 
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sulfhydryl reactive agents and have been n to react with Kelch-like ECH associated 
protein-1 (Keap1) [18, 21], an inhibitor of Nrf2. The Kelch-like ECH–associated 
protein 1 (Keap1) is a cysteine rich protein and serves as a regulator of Nrf2. Keap1 
and Nrf2 play a central role in the protection of cells against antioxidants and 
sensitizers through inducing expression of many cytoprotective genes such as 
carboxylesterase1. Under uninduced conditions, Nrf2 is ubiquitinated by the complex 
and rapidly degraded in proteasomes. This degradation processes regulate Nrf2 
protein and induce stabilization of Nrf2. Upon exposure to antioxidants and 
sensitizers, these small molecules interact with the reactive cysteine residues of Keap1 
and lead to dissociation of Nrf2 from Keap1-Nrf2 complex. Nrf2 translocates from 
cytoplasm to nucleus and transactivates target genes Nrf2 show transactions through 
binding with antioxidant response element of (ARE) in the promoter regions of 
upstream regulatory sequences [51-54]. Interaction with Keap1 by sensitizers leads to 
Nrf2 activation. Different patterns of cysteine modification of Keap1 show distinct 
biological outputs [51, 53]. The magnitude of the activation was correlated with their 
sensitizing potency [18]. 
There are three different types of inhibition of activity. The first type of inhibition is 
competitive inhibition. That means the ester compounds metabolized by the same 
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carboxylesterases and causes the hydrolysis rates to vary. The typical example is the 
interaction between clopidogrel and oseltamivir. Both of them are substrates of CES1, 
but clopidogrel has a higher hydrolysis rate than oseltamivir [34]. Based on that, 
oseltamivir has as low as 10% of the normal hydrolysis rate when the same 
concentration of clopidogrel is present. Oseltamivir is the prodrug and only the 
hydrolysis metabolite has a therapeutic effect with lower toxicity. When oseltamivir is 
administered with clopidogrel, the therapeutic outcome is decreased around 90% and 
the neurotoxicity is increased [55-57]. Serine enzyme inhibitors are the second type of 
CES inhibitors. This type of inhibitors can irreversibly bind and change the active-site 
serine residues. Transitional analog inhibitors are the third type of inhibition. They 
reversibly interact with the active-site serine residues [34, 58-62]. 
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4. Functional consequence of carboxylesterase 
Carboxylesterases are hydrolytic enzymes and functionally interact with other 
metabolic enzymes to clear xenobiotics. The pharmacogenomics of carboxylesterases 
is an important issue because CES leads to one of the first steps of the 
biotransformation pathway. The metabolites of CES associated with other enzymes 
and transporters form complicated networks. Therefore, the variability of CES may 
link to the significant clinical outcomes reported [63-67].  
Many drugs are metabolized by multiple enzymes such as the carboxylesterases and 
cytochrome P450 (CYP) systems. The availability of a drug is usually determined by 
hydrolysis, because it happens faster than other reactions. The clinical effect of some 
ester prodrugs depends on the competition of hydrolysis by CES and oxidation by 
CYP. For example, clopidogrel, an antiplatelet agent, loses its pharmacological 
activity by hydrolysis by CES1 [3] but activates by CYP2C19, CYP3A4 and to a 
lesser extent, other CYP enzymes (Figure 1.) [35, 68-70]. Around 95% of clopidogrel 
undergoes the hydrolysis and only 5% is oxidized to active metabolite [3]. The active 
metabolite interacts with the purinergic receptor P2Y, G-protein coupled, 12 (P2Y12 
receptor) and partitions them out of lipid rafts [71]. On the other hand, prasugrel, 
another antiplatelet agent, has to be metabolized by CES2 then by multiple CYP 
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enzymes and becomes finally an active compound [35, 68]. Other antiplatelet agent, 
acetylsalicylic acid, is also hydrolyzed by CES. After hydrolyzing it, its hydrolytic 
metabolite loses 90% of antiplatelet abilities. The combination of these substrates of 
CES enzymes may increase their antiplatelet abilities and cause unexpected clinical 
effects. Iirinotecan, anticancer agent, a carboxylic acid ester prodrug, is rapidly 
hydrolyzed by CES2 to the active metabolite SN-38 to kill cells. On the hand, 
Iirinotecan also undergo metabolism by CYP 3A4. More importantly, the metabolites 
have different functionality. Iirinotecan metabolized by CES2 represents the 
activation and metabolized by 3A4 represents the inactivation [72] (Figure 1.4). 
Beside the pharmacological interactions, induction of CES1 may have 
pathophysiological significance as well. CES1 hydrolyzes many endogenous esters [2, 
4, 5]. Hydrolysis of cholesterol esters increases free cholesterol and the synthesis of 
bile acids to eliminate excessive cholesterol [4]. On the other hand, the increasing of 
hydrolyzing triglycerides and cholesterol esters may increases the synthesis and 
secretion of very low density lipoprotein (VLDL) and low density lipoprotein (LDL). 
Indeed, high CES1 activity has been shown to facilitate VLDL maturation [10, 73, 74]. 
Transgenic expression of human CES1 in mice leads to increased secretion of apoB 
proteins and plasma triglycerides [10]. Elevated levels of LDL increase the risk of 
16 
 
developing atherosclerosis [75]. Moreover, young patient treated with phenobarbital, 
a CES1 inducer, has been observed to have higher plasma total cholesterol and 
low-density-lipoprotein cholesterol [76]. Therefore, excessive induction of CES1 
without enhancing bile acid synthesis likely has a detrimental effect.  
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figu
 
 
re 1.3 Metabolic activations of ir
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ABSTRACT 
 
Carboxylesterase-2 (CES2) and cytochrome P450 3A4 (CYP3A4) are two major drug metabolizing 
enzymes that play critical roles in hydrolytic and oxidative biotransformation, respectively.   In many 
cases, CES2 and CYP3A4 share substrates such as the anticancer prodrug irinotecan and present opposite 
outcomes in terms of therapeutic activity.  CES2 and CYP3A4 are both expressed in the liver and the 
gastrointestinal (GI) tract. The present study was conducted to determine whether CES2 and CYP3A4 are 
expressed under developmental regulation and whether the regulation occurs in an organ-dependent 
manner. Liver and duodenal tissues were collected from various ages. The liver tissues were divided into 
5 age groups: I (1-31 days), II (35-70 days), III (89-119 days), IV (123-198) and IV (≥ 18 years of age). 
The duodenal tissues were divided into 4 groups: D1 (1-70 days), D2 (76-141 days), D3 (163-332 days) 
and D4 (≥ 18 years).  In addition, multi-sampling (liver, duodenum and jejunum) was performed in some 
donors. The expression was determined at mRNA and protein levels. In the liver, the levels of CES2 and 
CYP3A4 mRNA exhibited a  postnatal surge  (group I  versus II)  by  2.7  and  29  fold, respectively. 
CYP3A4 but not CES2 mRNA in certain pediatric groups reached or even exceeded the adult level.  The 
duodenal samples, on the other hand, showed a gene-specific expression pattern at mRNA level.  The 
level of CES2 mRNA increased with age but the opposite was true with CYP3A4 mRNA.  The levels of 
CES2 and CYP3A4 protein, on the other hand, increased with age in both liver and duodenum.   The 
multi-sampling study demonstrated significant correlation of CES2 expression between the duodenum 
and jejunum.   However, neither duodenal nor jejunal expression correlated with hepatic expression of 
CES2.   These findings establish that developmental regulation occurs in a gene and organ-dependent 
manner. 
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1. INTRODUCTION 
 
Personalized medicine is an ultimate goal of health professionals and inter-individual variability presents 
the major challenge to achieve this goal [1-4].  While many factors are contributing to inter-individual 
variability, biotransformation is recognized as one of the major contributing factors [3, 4].   There are 
three types of biotransformation, commonly referred to as phase I [5], phase II [6] and phase III reactions 
[7].   Phase I and II reactions are accomplished by drug-metabolizing enzymes.   Phase III reactions, 
without chemical modifications, are accomplished by drug transporters.   The human genome contains 
~150 biotransformation genes with known pharmacological and toxicological significance [3-7].  Many 
biotransformation genes are expressed in a wide range of organs and tissues.  However, the highest 
expression of many biotransformation genes occurs in the liver and the gastrointestinal (GI) tract [8, 9]. 
The expression of these genes, on the other hand, exhibits large inter-individual variability, up to 100-fold 
in some cases [10].  Genetic and environmental factors as well as disease status are known to regulate the 
expression of these genes [11-13]. 
   
We and investigators have shown that the expression of biotransformation genes is developmentally 
regulated in rodents and humans [14-18].  Based on immunoblotting analysis [16], one to two week old 
rats express no hydrolase A or B, two major rat carboxylesterases.  Consistent with little expression of 
carboxylesterases, the intrinsic hydrolytic clearance of the pyrethroid deltamethrin in 10-day old rats is 
only ~3% of adult rats [19].  Even in 4-week old rats, the intrinsic clearance is less than half of that of 
adults [19].   In addition, young animals are generally much more sensitive to pesticides such as 
organophosphates and pyrethroids [20, 21].   Carboxylesterases are known to protect against these 
chemicals by hydrolysis in the case of pyrethroids or scavenging mechanism in the case of 
organophosphates.  Human carboxylesterase-1 (CES-1) and 2 (CES2) in the liver are developmentally 
regulated [15, 22, 23]. 
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We recently showed that the developmental regulation of CES1 in the liver consists of a postnatal surge 
followed by an incremental increase throughout the entire adolescence [15, 22].  Based on the level of 
CES1 mRNA, the postnatal surge of CES1 is completed two months after birth [22].  The present study 
was undertaken to determine whether the ontogenic expression pattern of CES1 represents a common 
phenomenon among biotransformation genes.  This study focused on CES2 and cytochrome P450 3A4 
(CYP3A4).  CES2 and CES1 together represent as much as 90% of hydrolytic capacity toward drugs and 
other xenobiotics [24, 25]. CYP3A4 is a member of the cytochrome P450 mixed-function oxidase system 
[26].  This oxidase is involved in the metabolism of more than 50% drugs and other xenobiotics.  CES2 
and  CYP3A4 are  functionally linked in  terms of  tissue distribution and  coupled metabolism.   For 
example, both CES2 and CYP3A4 are abundantly expressed in the liver and the GI tract [8, 27, 28]. 
Importantly, some drugs are  metabolized by  both CES2 and CYP3A4.   Their relative activity has 
profound therapeutic consequences [29].  The anticancer drug irinotecan, for example, is hydrolyzed to 
produce SN-38, a metabolite with potent anticancer activity.  In contrast, irinotecan undergoes oxidation 
by CYP3A4 to produce two major oxidative metabolites: NPC (7-ethyl-10-(4-amino-1-piperidino) 
carbonyloxycamptothecin and APC (7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] 
carbonyloxycamptothecin. Both NPC and APC are less active than the parent compounds [29]. 
  
 
This study tested a large number of human liver and duodenal samples for the expression of CES2 and 
CYP3A4 by Western blotting and reverse transcription-quantitative polymerase chain reaction (RT- 
qPCR).  In the liver, the levels of CES2 and CYP3A4 mRNA exhibited a postnatal surge (group I versus 
II) by 2.7 and 29 fold, respectively.  The duodenal samples, on the other hand, showed a gene-specific 
expression pattern at mRNA level.  CES2 mRNA increased with age but the opposite was true with 
CYP3A4 mRNA.   Nevertheless, CES2 and CYP3A4 protein increased with age in both liver and 
duodenum.  The multi-sampling study demonstrated significant correlation of CES2 expression between 
the duodenum and jejunum.  However, neither duodenal nor jejunal expression correlated with hepatic 
expression of CES2. 
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2. MATERIALS AND METHODS 
 
2.1. Chemicals and supplies 
 
Ponceau S was purchased from Sigma (St. Louis, MO).  TaqMan probes were from Life Technologies 
Corporation (Grand Island, NY).    The TaqMan assay identification numbers were: CES2, 
Hs00187279_m1 (NM_198061); CYP3A4, Hs00604506_m1 (NM_017460.3); and polymerase (RNA) II, 
Hs01108291_m1 (NM_000937).   Random primers and M-MLV reverse transcriptase were purchased 
from Promega Corporation (Madison, WI).  The RNAzol B reagent was from Tel-Test Inc (Friendswood, 
TX).    Antibody against glyceradehyde-3-phosphate dehydrogenase (GAPDH) was from Abcam 
(Cambridge, MA).  Unless otherwise specified, all other reagents were purchased from Fisher Scientific 
(Pittsburgh, PA). 
   
2.2. Preparation of RNA and S9 fractions 
 
A total of 102 tissue samples were used in this study including 59 liver, 33 duodenal and 10 jejunal 
samples. Multi-sampling was performed in 10 donors, thus, there was a total of 92 donors. Among them, 
69  were  pediatric (1-332 days  of  age)  and  23  adult  donors.    Majority of  the  donors (54%) were 
Caucasian-American.  The tissues were acquired primarily from the University of Maryland Brain and 
Tissue Bank for Developmental Disorders (Baltimore, MD). Total RNA was isolated with RNAzol B and 
the integrity was verified by agarose gel electrophoresis described previously [30].   S9 fractions were 
prepared by differential centrifugation as described previously [30].  The use of the human samples was 
approved by the Institutional Review Board. 
   
2.3. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) 
 
Total RNA (0.1 μg) was subjected to the synthesis of the first strand cDNA in a total volume of 25 μL 
 
with random primers and M-MLV reverse transcriptase [15].  The reactions were conducted at 25°C for 
 
10 min, 42°C for 50 min and 70°C for 10 min.  The cDNAs were then diluted 6 fold and qPCR was 
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performed with TaqMan Gene Expression Assay as described previously [15, 23].   The PCR amplifi- 
cation was conducted in a total volume of 20 µl containing universal PCR master mixture (10 µl), gene- 
specific TaqMan assay mixture (1 µl), and cDNA template (3 µl).  The cycling profile was 50°C for 2 
min, 95°C for 10 min, followed by 40 cycles of 15 s at 95°C and 1 min at 60 °C, as recommended by the 
manufacturer.  Amplification and quantification were done with the Applied Biosystems 7900HT Real- 
Time  PCR  System.    All  samples  were  analyzed  in  triplicate  and  the  signals  were  normalized  to 
polymerase (RNA) II and then expressed as relative levels of mRNA…. 
   
2.4 Western analysis 
 
S9 fractions (8-20 μg) were resolved by 7.5% SDS-PAGE in a mini-gel apparatus and transferred 
electrophoretically to nitrocellulose membranes.  In some cases, membranes were rinsed once in TBST 
buffer (20 mM Tris-HCl, 150 mM NaCl and 0.05% Tween 20) and then blocked in 5 % non-fat milk as 
described previously [24, 31].  In other cases, membranes were washed once in 0.1% acetic acid solution 
and stained in 0.1% Ponceau S solution for 5 min.  The membranes were then washed twice in 5% acetic 
acid solution and then blocked in 5 % non-fat milk.  The blots were incubated with an antibody against 
CES2, CYP3A4 and GAPDH, respectively. The preparation of the antibodies against CES2 and CYP3A4 
was described elsewhere [32].  In both cases, the antigens were peptides conjugated with keyhole limpet 
hemocyanin.  The sequence of CES2 peptide was H2N-CQELEEPEERHTEL-COOH, and of CYP3A4 
was H2N-CVKRMKESRLEDTQKHRVDFLQ-COOH. The primary antibodies were subsequently 
localized with goat anti-rabbit IgG conjugated with horseradish peroxidase, and horseradish peroxidase 
activity was detected with a chemiluminescent kit (SuperSignal West Pico).   The chemiluminescent 
signals signal was captured by Carestream 2200 PRO imager. 
  
 
2.5. Other analyses 
 
Protein  concentrations were  determined with  BCA  assay  (Pierce)  based  on  bovine  serum  albumin 
standard.  Data are presented as mean ± SD.  All enzymatic assays were repeated three times with the 
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same microsomal preparation.   Statistical analyses were performed with SPSS-PASW Statistics 20. 
Significant differences were tested according to Spearman for correlation or One-way ANOVA followed by 
a  DUNCAN’s test for comparison of means.   In all cases, significant differences were made when p 
values were less than 0.05. 
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3. RESULTS 
 
3.1. Expression of CES2 and CYP3A4 mRNA as a function of age 
 
We have shown that the expression of CES1 exhibits a two-phase developmental regulation: a fast surge 
in the early period after birth followed by an incremental phase toward the end of adolescence [15, 23]. 
This study was undertaken to determine whether the two-phase developmental regulation represents a 
common phenomenon among drug-metabolizing enzymes.  This study focused on CES2 and CYP3A4, 
two major drug-metabolizing enzymes [24-26].  CES2 and CYP3A4 share many substrates with different 
clinical consequences [29].  We initially tested a large number of individual liver tissues collected at birth 
to 198 days of age.  Samples were divided into several groups: I (1-31 days), II (35-70 days), III (89-119 
days) and IV (123-198 days). As a control, adult livers (i.e., group V) were included. Each group had 10- 
14 individual samples. Among them, 33 were male and 26 female donors (Table I). 
   
 
The expression of CES2 and CYP3A4 was determined by RT-qPCR with a Taqman probe and Western 
blotting.  As shown in Fig. 1 and Table II, the relative level of CES2 mRNA in group I-V was 26, 70, 88, 
80 and 100%, respectively.  The level of CYP3A4 mRNA in these groups was 2, 65, 110, 98 and 100%, 
respectively.  Clearly, both genes exhibited a postnatal surge (group I versus II) with a magnitude of 2.7 
and 29 fold, respectively.  For CES2 mRNA, none of the postnatal groups reached the adult level.  In 
contrast, the level of CYP3A4 mRNA in groups III and IV reached or even exceeded the adult level (Fig. 
1, Table II).  The levels of the corresponding proteins, on the other hand, showed a better age-dependent 
increase for both enzymes (Fig. 1).  The expression of mRNA for both genes exhibited large inter- 
individual variations with CYP3A4 mRNA being much greater (Fig. 1, Table I). 
   
3.2. Correlation of ontogenic expression between hepatic CES2 and CYP3A4 
 
Both CES2 and CYP3A4 mRNA exhibited a postnatal surge, however, the magnitude differed markedly 
(Fig. I and Table II).  In addition, the level of CYP3A4 but not CES2 mRNA in certain pediatric groups 
reached or even exceeded the adult level.   These observations pointed to potential differences in the 
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molecular mechanisms supporting the ontogenic regulation of these two genes.   To shed light on this 
possibility, correlation studies were performed on age as well as on each other.  As shown in Fig. 2A, the 
level of CES2 mRNA was significantly correlated with age and the correlation was slightly better during 
the period of 1-70 days of age (r = 0.359) than that of 0-198 days (r = 0.478). Similar trend of correlation 
was detected on the level of CYP3A4 mRNA over age (r = 0.350 versus r =0.539).  Importantly, the 
levels of CES2 and CYP3A4 mRNA were correlated well. The correlation coefficient for the period of 0- 
198 days was 0.318 and the correlation was much improved for the period of 1-70 days (r = 0.859), 
suggesting that the same or similar mechanism support the ontogenic expression of CES2 and CYP3A4, 
particularly during the first two months after birth. 
  
 
3.3. Duodenal expression of CES2 and CYP3A4 
 
In addition to the liver, the GI track expresses high levels of drug metabolizing enzymes [24-26].  We 
next tested whether the  duodenum shares with the  liver in  the  ontogenic expression of  CES2 and 
CYP3A4. A total of 43 duodenal samples were collected and divided into I (1-70 days), II (76-141 days), 
III (163-332 days) and IV (≥ 18 years) (Table III) with each group having 9-13 individual samples.  E As 
shown in Fig. 3A (Left), the levels of CES2 mRNA and protein exhibited age-related increases in groups I, 
II and III (Fig. 3, Table III), although the increase in CES2 mRNA between group III and IV was 
minimal (Table III).  The adult group, nevertheless, exhibited much greater individual variation in CES2 
mRNA (Left of Fig. 3A).  Ponceau S staining was used for the normalization of loading and transfer as 
the levels of several commonly used house-keeping proteins (e.g., GAPDH) showed large group-group 
variations.   The correlation of CES2 mRNA with age among the duodenal samples (0-332 days) was 
statistically significant (p < 0.017) and the correlation coefficient was 0.412  (Fig. 3A).  Interestingly, the 
correlation among the 0-96 day samples had a smaller coefficient (r = 0.283) and did not reach statistical 
significance. Overall, the correlation study demonstrated that CES2 mRNA exhibited a similar pattern of 
ontogenic expression in the liver and duodenum. 
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In contrast to the liver, CYP3A4 mRNA in the duodenum exhibited a major difference in the age-related 
expression.  The level of CYP3A4 mRNA in the liver was correlated positively with age (Fig. 1, Table 
II).   However, the level of CYP3A4 mRNA decreased with age (Left of Fig. 3B, Table IV).   In the 
duodenal samples, a 25% decrease of CYP3A4 mRNA was detected from group I (1-70 days) to groups II 
(76-141 days) or III (163- 332 days).   Overall, the level of CYP3A4 mRNA in the duodenal samples 
among pediatric donors was inversely correlated with age, although the inversed correlation did not reach 
the level of statistical significance (r = -0.145, p = 0.421).  Interestingly, during the first three months 
after birth (1-96 days), the level of CYP3A4 mRNA showed a trend of positive correlation with age (r = 
0.184, p = 0.546) (Fig. 3B).   Nevertheless, none of the correlation coefficients reached statistical 
significance.  Among all duodenal samples, large individual variations were detected with coefficients of 
variance ranging from 1.78 to 2.46 (Table IV).   The adult duodenal samples, compared with group I 
sample, showed a 67% decrease in CYP3A4 mRNA (Left of Fig. 3B).   Interestingly, the level of 
CYP3A4 protein in this group was much higher than that of all other duodenal groups (pediatric donors). 
   
3.4. Organ-specific ontogenic expression of CES2 
 
The studies with groups-based samples demonstrated large individual variations, although the variations 
tended to be smaller with the liver samples (Figs. 1 and 3).  To minimize potential individual variations, 
we next determined the expression of CES2 in the liver and intestinal samples from the same donors. 
This was of significance as this study would specify whether individuals expressing relatively high levels 
of CES2 in the liver also express high levels of this enzyme in his/her GI track.   We collected liver, 
duodenum and jejunum from 10 individuals.  With an exception of a single adult donor, all donors were 
pediatric from 1 to 196 days of age.  Once again, both RT-qPCR and Western blotting were used for the 
expression determination.  CES2 mRNA but not for CES2 protein was detected in all samples.  While 
there were exceptions, the relative abundance of CES2 protein occurred in an order of the liver, the 
duodenum and the jejunum (Fig. 3A).  Donor 10, on the other hand, expressed the highest level of CES2 
protein in the duodenum.  Donor 3 expressed comparable levels of CES2 protein among all three organs 
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and donor 4 did not express detectable CES2 protein in either organ.  Based on the level of CES2 rnRNA， 
 
duodenal  and  jejunal  exp 自 ssion  was  significantly  correlated  with  a coefficient  of 0.359 (p 0.023) 
However  neither duodenal nor jejunal exp 自  ssion was correlated liver expression (Fig. 4B) 
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4. DISCUSSION 
 
Individualized  medicine  is  an  ultimate  goal  of  health  professionals  and  inter-individual  variability 
presents  the  major  challenge  for  individualized  medicine  [1-4].    Biotransformation  is  the  major 
contributor to individual variability [3, 4].   In adults, the expression of drug-metabolizing enzymes is 
regulated largely by environmental factors, whereas in children, environmental and developmental factors 
are both involved in the regulatory process [15, 23].  We have recently made a concerted effort and laid 
groundwork on the ontogenic expression of biotransformation genes.   In this study, we tested a large 
number of liver and small intestinal samples from pediatric donors for the expression of CES2 and 
CYP3A4, two major drug-metabolizing enzymes [24, 26].   While both genes were developmentally 
regulated, the overall outcomes varied depending on a gene and an organ.  In the case of CES2, age- 
dependent increases were detected in the liver and the GI tract at both mRNA and protein levels (Figs. 1 
and 2).  However, the age-related increases in CYP3A4 were detected at protein in both organs but not 
mRNA (Figs. 1 and 2). 
   
The results described in this study, nevertheless, point to an important conclusion about ontogenic 
expression in human liver.  Namely, the postnatal surge, although exceptions may exist, is a general 
phenomenon among biotransformation genes.   The magnitude of the surge, on the other hand, varied 
depending on a gene.  Based on RT-qPCR analysis, the level of CYP3A4 mRNA showed a surge by 29- 
fold, but the level of CES2 mRNA by 2.7 fold only (Fig. 1).  We previously reported a 7.1-fold postnatal 
surge of CES1 mRNA. The surge of CES2 and CYP3A4 mRNA represented 65-70% of the level in adult 
liver, whereas in the case of CES1, it represented 50% only [23].  Following the surge was gradual 
increases in mRNA expression during the 6 months after birth.  However, such increases varied markedly 
from a gene to another. In the case of CES2, 10-20% increases were detected from 70 to 198 days of age, 
but the level of CES1 mRNA was increased by only 5% during this period.   The level of CYP3A4 
mRNA, on the other hand, was increased by as much as 45%.  As a matter of fact, the level of CYP3A4 
mRNA in groups III (89-119 days) and IV (123-198 days) reached or even exceeded the adult level (Fig. 
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1).  In contrast, the surge of CES2 mRNA was followed by an incremental increase toward adulthood, 
which was similar to that of CES1 mRNA.  However, the incremental phase of CES2 mRNA represented 
less percentage than that of CES1 (20 vs. 50%) (23, Fig. 1). 
   
The level of CYP3A4 but not CES2 mRNA displayed organ-specific ontogenic expression patterns.  The 
hepatic expression of CYP3A4 mRNA, like CES2 mRNA, was correlated significantly during the first six 
months of life (r = 0.350, p = 0.027) (Left of Fig. 2B).  Similarly to CES2 mRNA, CYP3A4 mRNA was 
correlated much better with age (r = 0.539, p < 0.014) when the period of the first 70 days was considered 
(Right  of  Figs.  2A  and  B).    Importantly,  levels  of  CES2  and  CYP3A4  mRNA  were  correlated 
significantly with each other (Fig. 2C).   These findings suggested that CES2 and CYP3A4 share 
mechanisms in ontogenic expression, at least in light of hepatic mRNA expression.  In contrast, the 
duodenum exhibited different expression patterns between CES2 and CYP3A4 mRNA.   A positive 
correlation during the first 70 days was detected for both genes (Right of Fig. 3).  However, the overall 
correlation during the first 198 days was opposite.  The abundance of CYP3A4 mRNA was negatively 
correlated with age, while the level of CES2 mRNA positively with age in the duodenum (Fig. 3). 
   
The multi-organ sampling study provided important information on inter-organ differences in terms of 
gene expression. While the level of CES2 mRNA increased with age in both liver and duodenum, hepatic 
and duodenal levels from the same donors showed insignificant correlation (Fig. 4B).  On the other hand, 
duodenal and jejunal levels of CES2 mRNA were significantly correlated (Fig. 4B).  The insignificant 
correlation between the liver and small intestine suggests that the developmental regulation is mediated 
by different triggers in these two organs.  The precise mechanisms remain to be determined, and many 
changes take place immediately after birth and in the early days/weeks of life, notably on hormones and 
food intake. On the other hand, many biotransformation genes are expressed in a rapid increasing manner 
such as CYP3A4 and CES1.  For example, fibroblast growth factor-21 (FGF-21) is induced rapidly [33], 
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and importantly the induction of FGF-21 was diminished in mice lacking functional peroxisome 
proliferator-activated receptor-α (PPARα) [33]. 
   
It happens that this receptor has been implicated in the regulation of the expression of carboxylesterases 
in rodents [16, 34, 35], although its involvement in the regulated expression of human carboxylesterases 
remains to be established.  On the other hand, the CES2 promoter region contains two PPARα putative 
elements located -907 and -256, respectively [36].   It has been reported that the CES2 gene has three 
promoters, designated promoter-1, promoter-2 and promoter-3, respectively.   These promoters use 
different transcription start sites, thus producing distinct transcripts.   It appears that promoter-3 has a 
broad tissue activity and supports constitutive but low level of expression.  In contrast, promoter 1 and 
promoter 2 show tissue-dependent activity.   For example, promoter 1 is more active in the liver than 
promoter 2, and the opposite is true in the small intestine [36].  Interestingly, one of the PPARα putative 
elements is present in promoter 1 and the other in promoter 2.  Given the observation that the liver but not 
small intestine expresses high levels of PPARα [37, 38], the element in promoter 1 is likely involved in 
the developmental regulation of CES2 in the liver.  On the other hand, PPARδ and PPARγ are expressed 
much higher in the GI track.  Therefore, these two receptors likely play a role in the developmental 
regulation of CES2 in the GI tract [37].  While all PPARs are functionally related, they exhibit different 
ligand specificity [38].   An involvement of different PPARs in the developmental regulation of CES2 
between the GI and liver provides an explanation to the insignificant correlation on CES2 expression 
between these two organs, although both organs exhibited significant age-dependent expression (Figs. 1, 
2 and 3). 
    
In contrast to RT-qPCR, Western blotting consistently detected age-related increases regardless of genes 
(CES2 or CYP3A4) or organs (liver and duodenum) (Figs. 1 and 3).  The precise mechanisms remain to 
be determined on the disproportions between mRNA and protein expression of CES2 and CYP3A4.  In 
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particular, duodenal samples in the adult group had the lowest CYP3A4 mRNA, but the same group 
expressed the highest level of CYP3A4 protein (Left of Fig. 3B).  It is likely that the translational 
efficiency of intestinal CYP3A4 mRNA increases with age.  Alternatively, the expression of certain 
microRNAs (miRs) that target CYP3A4 transcript increases and thus negatively affects the production of 
CYP3A4 proteins.   In support of this possibility, several miRs have been reported to regulate the 
expression of CYP3A4 [39] or the pregnane X receptor, a major regulator of CYP3A4 expression in 
response to xenobiotic stimuli [40].  Nevertheless, it remains to be determined whether these miRs are 
expressed in an age-dependent manner. 
   
The precise pharmacological significance of the organ-specific expression remains to be established.  In 
the case of CES2, the contribution to the overall hydrolysis between the liver and GI is likely closer than 
the difference in the expression.  In this study, the entire wall of the small intestine was used.  It is not 
clear whether CES2 is present in the whole section of the wall or primarily in the mucosal layer.  Based 
on the study in the puppies [41], the mucosal layer takes 60-70% of the thickness of the entire wall. 
Therefore, the expression levels were probably underestimated if CES2 is exclusively present in the 
mucosal layer.  Likewise, the presence of CES2 in the liver may not be uniform.  We previously showed 
that several rat carboxylesterases were primarily located in the centrilobular regions [42, 43].  Finally, the 
initial concentrations of drugs and other xenobiotics in the small intestine are much higher than those in 
the liver after oral administration.  Therefore, it is likely that the GI track contributes much greater to the 
overall hydrolysis than the levels expression. 
   
In summary, our work points to several important conclusions.  First, the postnatal surge of mRNA 
expression in the liver, although exceptions may exist, is a general phenomenon among biotransformation 
genes.   Second, high-levels of mRNA do not necessarily result in high-levels of protein, and such 
disproportions likely occur in an organ-specific manner. And third, individuals may disproportional drug- 
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metabolizing capacities between the liver and the GI tract, two major biotransformation organs.  These 
findings establish that developmental regulation occurs in a gene and organ-dependent manner. 
   
Footnotes 
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Table I. Demographic distribution of liver donors 
  
Group n Male/Female CA AA H 
 
I (1-31 days) 
 
12 
 
6/6 6 4 
 
2 
II (35-70 days) 13 5/8 5 8  
III (89-119 days) 10 7/3 4 6  
IV (123-198 days) 10 8/2 4 5 1 
V (≥18 years)    14  7/7  10  4   
 
Abbreviation: CA, Caucasian-American; AA, African American; H, Hispanic 
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Table II. Relative levels of liver CES2 and CYP3A4 mRNA in various age groups 
 
Group CES2 mRNA CYP3A4 mRNA 
 
I (1-31 days) 2.07 (1.57) 1.33 (1.79) 
II (35-70 days) 5.57 (3.45) 38.6 (34.4) 
III (89-119 days) 6.99 (2.63) 65.6 (101.8) 
IV (123-198 days) 6.36 (1.56) 58.6 (75.6) 
V (≥18 years) 7.96 (3.81) 59.7 (69.7) 
Note Data presented as mean ± SD (parenthesis) 
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Table I. Demographic distribution of duodenal donors 
  
Group n Male/Female CA AA H 
 
I (1-70 days) 
 
11 
 
3/8 6 5  
II (76-141 days) 9 7/2 3 6  
III (163-332 days) 13 9/4 7 6  
V (≥18 years)  10  5/5  8  2   
 
Abbreviation: CA, Caucasian-American; AA, African American; H, Hispanic 
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Table IV. Relative levels of duodenal CES2 and CYP3A4 mRNA in various age groups 
 
Group CES2 mRNA CYP3A4 mRNA 
 
I (1-70 days) 2.71 (2.98) 19.7 (35.2) 
II (76-141 days) 3.42 (4.57) 14.2 (29.4) 
III (163-332 days) 6.33 (4.23) 15.3 (37.7) 
V (≥18 years) 6.62 (12.01) 6.61 (15.8) 
Note Data presented as mean ± SD (parenthesis) 
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LEGENDS FOR FIGURES 
 
Fig. 1. Hepatic expression of CES2 and CYP3A4 as a function of age Total RNAs from livers were 
subjected to RT-qPCR analysis for the levels of CES2 or CYP3A4 mRNA by Taqman probe as described 
in the section of Materials and Methods.  The signals from each target were normalized based on the 
signal from Pol II and expressed as relative levels among all samples.  The data are presented as mean ± 
SD.  For Western analysis S9 fractions (7.5 μg for CES2 and 10 μg for CYP3A4) were resolved by 7.5% 
SDS-PAGE and transferred electrophoretically to nitrocellulose membranes.  The samples were pooled 
with the same amounts of proteins from individual samples in the same group.  The blots were incubated 
with an antibody against CES2, CYP3A4 or GAPDH and developed with chemiluminescent substrate. 
The signal was captured by Carestream 2200 PRO imager. *Statistical significance at p < 0.05. 
   
Fig. 2. Correlation analyses between age and levels of CES2 or CYP3A4 mRNA The correlation was 
performed with SPSS Statistics 20.   (A) Correlation of CES2 mRNA as a function of age:1-198 days 
(Left) or 1-70 days (Right).  (B) Correlation of CYP3A4 mRNA as a function of age:1-198 days (Left) or 
1-70 days (Right).  (C) Correlation of CES2 over CYP3A4 mRNA as a function of age:1-198 days (Left) 
 
or 1-70 days (Right). Correlation coefficients and corresponding p values are shown. 
  
  
Fig. 3. Duodenal expression of CES2 and CYP3A4 as a function of age and correlation analyses (A) 
Duodenal expression of CES2 Total RNAs from duodena were subjected to RT-qPCR analysis for the 
levels of CES2 mRNA by Taqman probe and the signals from each target were normalized based on the 
signal from Pol II and expressed as relative levels among all samples.  The data are presented as mean ± 
SD.  For Western analysis S9 fractions (10 μg) were resolved by 7.5% SDS-PAGE and transferred 
electrophoretically to nitrocellulose membranes. The blot was stained by 0.1% Ponceau S as described in 
the section of Materials and Methods.  Thereafter the blot was incubated with an antibody against CES2 
or GAPDH and developed with chemiluminescent substrate.   The signal was captured by Carestream 
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2200 PRO imager.  Once again, the correlation of CES2 mRNA as a function of age was performed with 
SPSS  Statistics  20.    (B)  Duodenal  expression  of  CYP3A4  All  procedures  for  the  expression  and 
correlation analysis for CYP3A4 were the same as described above.  However, the Western blotting used 
20 μg of S9 fractions. *Statistical significance at p < 0.05. 
    
Fig. 4. Multi-sampling study on the expression of CES2 Liver, duodenal and jejunal S9 fractions (8 
μg) were resolved by 7.5% SDS-PAGE and transferred electrophoretically to nitrocellulose membranes. 
The blots were stained by 0.1% Ponceau S and then incubated with an antibody against CES2 or GAPDH 
and developed with chemiluminescent substrate.   The signal was captured by Carestream 2200 PRO 
imager.   Once again, the correlation of CES2 mRNA between duodenum and jejunum (Left) or liver 
jejunum was performed (Right) with SPSS Statistics 20.  Correlation coefficients and corresponding p 
values are shown. 
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ABSTRACT 
Aims Carboxylesterase-1 (CES1), the most versatile human carboxylesterase, plays critical 
roles in drug metabolism and lipid mobilization.  This enzyme is highly induced by antioxidants 
and sensitizers.  These compounds are known to activate nuclear factor-E2 related factor-2 
(Nrf2) by reacting to kelch-like ECH-associated protein-1 (Keap1).  The aims of this study were 
to determine whether antioxidant sulforaphane (SFN) and sensitizer trinitrobenzene sulfonate 
(TNBS) target Keap1 similarly and whether they use the same element for CES1 induction. 
Results Two elements (S/ARE and ARE4) were identified to support Nrf2 in the regulated 
expression of CES1A1.  Both elements were bound by Nrf2, however, the S/ARE element 
supported whereas the ARE4 element repressed the transactivation of Nrf2.  The repression 
required higher amounts of Nrf2.  SFN promoted intramolecular oxidation whereas TNBS 
promoted intermolecular oxidation of Keap1.  
Innovation This study reports an Nrf2 repressive element although this transcription factor 
generally confers transactivation activity.  SFN and TNBS, both activating the Keap1-Nrf2 
pathway, react differently to Keap1.    
Conclusion Both positive and negative Nrf2 elements exist even within the same gene.  
Common activators of Nrf2 may differ in the molecular recognition of Keap1.  High levels of 
CES1 are linked to lipid retention.  Excessive induction of CES1 by antioxidants and sensitizers 
likely provides a mechanism for potential detrimental effect on human health.   
 
 
 
 
 
Chen et al. (2012) 
 68
INTRODUCTION 
Carboxylesterases (CES, E.C.3.1.1.1) constitute a large class of enzymes that play important 
roles in drug metabolism and lipid mobilization [1-4].  In the human genome, seven 
carboxylesterase genes are identified [1].  However, only three are catalytically characterized 
including CES1, CES2 and CES3 [5].  CES1 is encoded by two distinct genes: CES1A1 and 
CES1A2 [1], but CES1A1 is normally expressed to a greater extent [6].  CES1 is the most 
versatile human carboxylesterase and catalyzes hydrolytic, synthetic and transactivation 
reactions.  While all carboxylesterases are found to play roles in drug metabolism, emerging 
evidence links the sustained high-level expression of CES1 to the increased risk of developing 
cardiovascular diseases, obesity and insulin resistance [7-9].     
 
Antioxidants and skin sensitizers are two types of compounds recently shown to induce CES1 
[10-13].  Some sensitizers induced CES1 by as many as 20 fold [111].  The precise mechanism 
on the sensitizer-induction remains to be established.  The induction of CES1 by antioxidants, 
on the other hand, is mediated by Nrf2 (nuclear factor-E2 related factor-2) [14].  This 
transcription factor recognizes antioxidant response element (ARE) and confers potent 
transactivation [15].  RNA interference against Nrf2 abolished CES1 induction by antioxidants 
[14].  However, a native promoter reporter containing putative AREs was repressed by Nrf2 [14].  
Majority of skin sensitizers, on the other hand, are sulfhydryl reactive agents and shown to react 
with kelch-like ECH-associated protein-1 (Keap1) [10, 13], an inhibitor of Nrf2.  Interaction with 
Keap1 by sensitizers leads to Nrf2 activation.  The magnitude of the activation was correlated 
with their sensitizing potency [10].   
 
The present study was performed to test the hypothesis that both antioxidants and sensitizers 
react to Keap1 and causes transactivation of CES1A1 via a novel Nrf2 element.  To test this 
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hypothesis, Keap1-transfected cells were treated with sensitizer trinitrobenzene sulfonate 
(TNBS) or antioxidant DL-sulforaphane (SFN) and various molecular species of Keap1 were 
determined.  In contrary to the hypothesis, SFN promoted intramolecular oxidation whereas 
TNBS promoted intermolecular oxidation of Keap1.  To locate the element supporting the 
transactivation, the regulatory sequence of the CES1A1 gene was dissected and tested for the 
responsiveness to TNBS, SFN or Nrf2.  Two elements were identified and designated as S/ARE 
(sensitizing/antioxidant response element) and ARE4, respectively.  Interestingly, the S/ARE 
element supported Nrf2 transactivation whereas the ARE4 repressed it although the S/ARE 
element was a more sensitive target of Nrf2.    
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RESULTS 
CES1 induction by SFN and TNBS in primary cultures and cell lines   
Humans are exposed to antioxidants and sensitizers primarily through the gastrointestinal track 
and skin.  We first confirmed whether CES1 is induced by SFN and TNBS in primary cultures 
and cell lines from these organs.  Cells were treated with SFN or TNBS and CES1 expression 
was determined initially by RT-qPCR with a Taqman probe.  This probe recognizes both 
CES1A1 and CES1A2 mRNA.  In addition, the mRNA level of NAD(P)H:quinone oxidoreductase 
(NQO1), an Nrf2 target gene [16], was determined as well.  As summarized in Fig. 1, both SFN 
and TNBS significantly increased CES1 and NQO1 mRNA.  The highest induction of CES1 
mRNA was 3.9 fold and occurred in Huh7 cells treated with SFN (Fig. 1D) and the least (1.6 fold) 
in primary hepatocytes treated with TNBS (Fig. 1C).  In contrast, the highest induction of NQO1 
mRNA was 5.7 fold and occurred in primary hepatocytes (Fig. 1C), the least (1.9 fold) in primary 
fibroblasts treated with SFN (Fig. 1A).  Except for HT1080 cells, SFN caused greater induction 
of CES1 than TNBS, and NQO1 mRNA was induced to a greater or comparable extent by 
TNBS (Fig. 1).  In HT1080 cells, TNBS caused slightly higher induction of CES1 mRNA than 
SFN but the opposite was true on NQO1 induction (Fig. 1B).  Both SFN and TNBS markedly 
increased CES1 protein (Fig. 1E). 
 
Stimulation of the CES1A1 promoter by SFN, TNBS and Nrf2 
Nrf2 was implicated in the induction of CES1A1 by antioxidants including SFN [14], and many 
sensitizers are potent activators of Nrf2 [13].  We next tested whether TNBS and SFN induce 
CES1A1 via the same Nrf2 element.  Reporters were prepared to contain the CES1A1 promoter 
and upstream sequence at varying length.  As shown in Fig. 2A (Middle), reporters containing 
upstream sequence of 3582 bp (i.e., -3582) or further responded to both SFN and TNBS.  The 
CES1A1-3582-Luc reporter was activated the most (Fig. 2A).  In contrast, the other reporters, 
containing shorter sequence than the CES1A1-3582-Luc reporter, were suppressed by both 
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chemicals, and the suppression was greater on CES1A1-3432-Luc and CES1A1-2293-Luc than 
CES1A1-1426-Luc (Middle of Fig. 2A).   
 
Next we tested whether these reporters show a similar pattern of response to Nrf2.  Huh7 cells 
were transfected with a reporter, along with Nrf2 or the vector.  Consistent with the results on 
the TNBS and SFN treatment, the sequence from -3582 to -3432 was identified to support Nrf2-
transactivation (Fig. 2A, Right).  Likewise, the CES1A1-3432-Luc and CES1A1-2293-Luc 
reporters were repressed by Nrf2 (Right of Fig. 2A).   To further narrow down the sequence 
supporting the action of Nrf2, deletions of the CES1A1-3582-Luc reporter were made from the 5’ 
end and the resultant reporters were tested for the lost responsiveness to Nrf2.  As shown in Fig. 
2B, the reporter 1A1-3492-Luc but not 1A1-3482-Luc was transactivated by Nrf2.  Actually, the 
1A1-3482-Luc reporter was repressed by Nrf2.  These findings suggest that the 10-base 
sequence from -3492 to -3482 was critical for Nrf2-transactivation.   
 
Characterization of the S/ARE element  
The study with deletion mutants suggested that this 10-base sequence contains or is part of the 
Nrf2/TNBS/SFN response element: designated the S/ARE element.  We next performed a set of 
experiments to characterize this element.  We first tested whether Nrf2 binds S/ARE element 
and whether this binding can be competed by ARE4, an element previously identified to support 
Nrf2-transactivation [14].  As shown in Fig. 3A, incubation of a biotin-labeled S/ARE probe with 
nuclear extracts from SFN-treated cells produced a shifted band (lane 2).  This band was 
eliminated by an Nrf2 antibody (lane 3) and competed by non-labeled S/ARE (lanes 4 and 5), 
but not its mutant (lanes 6 and 7).  In addition, non-labeled ARE4 element effectively competed 
the binding as well (lanes 8 and 9).  Nevertheless, this experiment demonstrated that both the 
S/ARE and ARE4 were bound by Nrf2.  We next tested whether the S/ARE-containing 
sequence is intracellularly occupied by Nrf2.  ChIP analysis was performed with an Nrf2 
Chen et al. (2012) 
 72
antibody and the precipitated DNA was detected for the enriched S/ARE- or ARE4-fragment.  
As shown in Fig. 3B, comparable amplifications were detected with the input on both S/ARE- 
and ARE4-fragments, however, the ChIPed DNA produced robust amplification of the S/ARE- 
but not ARE4- fragment (Fig. 3B).  As expected, no amplification was detected with sample 
precipitated with pre-immune IgG. 
 
Activation of the S/ARE element reporter by SFN, TNBS and Nrf2   
The EMSA and ChIP experiments demonstrated that the S/ARE element serves as a major site 
for Nrf2 to interact with the CES1A1 gene.  We next tested whether the interaction confers 
biological activities.  Three reporters were tested including the S/ARE, CES1A1-3582-Luc and 
CES1A1-3582m-Luc reporters (Fig. 4A).  The CES1A1-3582m-Luc, a mutant of the CES1A1-
3582-Luc, had the S/ARE element replaced with its mutant sequence (Table I).  Cotransfection 
was performed to test the responsiveness of these reporters to SFN, TNBS and Nrf2.  As shown 
in Fig. 4B, SFN at 0.5 µM significantly activated the S/ARE reporter and the CES1A1-3582-Luc 
(bars labeled with different letters).  Higher concentrations caused higher activation of both 
reporters except 10 µM on the S/ARE reporter (Fig. 4B).  In contrast, none of the concentrations 
activated the CES1A1-3582m-Luc reporter.  Actually this mutant reporter was suppressed 
somewhat, although the suppression did not reach the level of statistical significance (Fig. 4B).  
Similar responding patterns to TNBS were detected (Fig. 4C).   Likewise, Nrf2 increased the 
activities of S/ARE and CES1A1-3582-Luc but not CES1A1-3582m-Luc reporter (Fig. 4D).  
However, several notable differences were observed (Fig. 4D): (a) Nrf2 caused slightly less 
activation of the CES1A1-3582-Luc than the S/ARE reporter, when Nrf2 was assayed at 1-10 ng; 
(b) Nrf2 at 20 ng, the highest concentration used, caused less activation of both reporters; and 
(c) it was surprising that higher amounts of Nrf2 (10 and 20 ng) significantly repressed the 
mutant reporter CES1A1-3582m-Luc (Fig. 4D). 
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Activation comparison of S/ARE element with other Nrf2 elements 
The EMSA, ChIP and reporter experiments established that the S/ARE element supported 
robust responsiveness to SFN, TNBS and Nrf2.  Next, we compared the responding potential of 
this element with well-characterized Nrf2 elements.  Reporters harboring the CES1A1-ARE4 
element or the corresponding CES1A2-S/ARE were also included.  In addition to Nrf2, these 
reporters were tested for their responsiveness to Nrf1, an Nrf2 functionally related protein [17].  
For direct comparison, reporters were prepared to contain a single copy of an ARE element.  As 
shown in Fig. 5, all reporters were transactivated by Nrf1 and Nrf2 except Nrf1 on the NQO1 
reporter (Fig. 5F) and Nrf2 on the 1A1-ARE4 reporter (Fig. 5B).  In both cases, their activity was 
actually decreased, and the decrease was statistically significant in the 1A1-ARE4 reporter (Fig. 
5B).  With a single exception (i.e., 1A1-ARE4), Nrf2 caused greater activation than Nrf1 on all 
reporters tested.  The highest transactivation was detected with the CES1A1-S/ARE reporter 
(5.8 fold) followed by the CES1A2-S/ARE reporter (5.2 fold).  The CES1A2-S/ARE reporter 
(Figs. 5A and C), compared with its CES1A2-S/ARE counterpart, was activated to a greater 
extent by Nrf1.  In some other cases such as the reporter of GCLM (glutamate-cysteine ligase 
regulatory subunit), Nrf1 and Nrf2 caused comparable activation (Fig. 5E).     
 
Differential reactivity of SFN and TNBS toward Keap1  
In the Keap1-Nrf2 pathway, Keap1 is the initiator whereas Nrf2 is the executor.  Keap1 is a 
cysteine-rich protein and some of the cysteines serve as reactive targets for antioxidants and 
sensitizers.  As a result, Keap1 has three forms depending on the oxidative status of cysteines: 
reduced Keap1, intramolecular and intermolecular Keap1.  We took advantage of their 
differences in electrophoretic mobility and tested whether SFN and TNBS produce similar 
composition of these three Keap1 molecular species.  Cells were transfected with Keap1 and 
treated with SFN or TNBS at various concentrations and the cell lysates were then separated by 
non-reducing electrophoresis followed by Western blotting.  As shown in Fig. 6A, both SFN and 
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TNBS decreased reduced mouse Keap1.  Surprisingly they differed in increasing intramolecular 
and intermolecular Keap1.  SFN increased intramolecular Keap1 whereas TNBS increased 
intermolecular Keap1.  Similar changes were detected with human Keap1 (Fig. 5B).       
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DISCUSSION 
CES1 is the most versatile human carboxylesterase and catalyzes hydrolysis, synthesis and 
transesterification [1, 2].  In this study, we reports that TNBS and SFN efficaciously induced 
CES1 through Nrf2.  Two elements, S/ARE and ARE4, were identified to bind to Nrf2 (Fig. 3A), 
however, they exhibited opposite activities.  S/ARE supported transactivation whereas ARE4 
supported repression of Nrf2, although S/ARE was a more sensitive target (Figs. 4D and 5B).  
Actually, the S/ARE reporter was activated the most by Nrf2 among all ARE reporters (Fig. 5).  
Compared with all AREs, ARE4 differs by two nucleotides at the 4th and 5th position in the core-
sequence (Fig. 5H).  The ARE4 has GA whereas other AREs have CT in these positions.  How-
ever, a frequency matrix analysis has predicted that 18% of ARE elements have a G and 6% an 
A in the 4th and 5th position, respectively [18], suggesting that this dinucleotide substitution (i.e., 
CTGA) may not be entirely responsible for the observed repression by Nrf2 (Fig. 5B). 
 
It is likely that this GACT substitution works with flanking nucleotides and negatively responds 
to Nrf2.  Indeed, computer program ALGGEN-PROMO predicts that the ARE4 core-sequence 
overlaps with a Yin-Yang1 (YY1) element.  This element, CGTGAGACA, consists of 5’ flanking 
dinucleotide CG and seven nucleotides of the ARE4 core sequence (in italic) including the 
dinucleotide GA discussed above (Fig. 6).  Importantly, a recent study has shown that Nrf2 
negatively regulated the transcription of the fibrosis transmembrane conductance receptor gene 
(CFTR) through an YY1 element overlapped with an ARE (CAAATGACA underlined) [19].  
Although the CES1A1 YY1 element shares five nucleotides with the CFTR YY1 element, the 
CES1A1 YY1 element lacks the typical core nucleotides of YY1 element [19].  However, these 
authors detected YY1-Nrf2 complex [19], suggesting that YY1 and Nrf2 form heterodimers and 
bind to an YY1-Nrf2 composite site.  On the other hand, Nrf2 has been established to preferably 
form heterodimers with small Maf proteins and confer transactivation activity [20, 21], thus 
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dominating the repression through the YY1-Nrf2 mechanism [Fig. 6].  In support of this notion, 
the repression of CES1A1 reporters was evident when Nrf2 was highly expressed (Fig. 2A), or 
in the absence of the S/ARE element (Figs. 3D and 5B).  Nevertheless, a confirmation of YY1, 
along with Nrf2, in the suppression of CES1 will provide an example of how a very same gene 
can be regulated by the same transcription factor with opposite regulatory activity.  
 
Another interesting finding is that SFN and TNBS caused different changes in the overall 
conformation of Keap1.  SFN promoted thiol oxidation of Keap1 within Keap1 whereas TNBS 
promoted the thiol oxidation between two Keap1 molecules (Fig. 5).  Thus, TNBS induced the 
formation of large Keap1 complex.  The precise mechanism on the difference remains to be 
determined.  It is likely that TNBS activates the Keap1-Nrf2 pathway by directly reacting 
sulfhydryl groups of Keap1, whereas SFN activates it by altering the cellular oxidative potentials.  
In support of this possibility, TNBS but not SFN is potent sulfhydryl agent [22, 23].  However, it 
remains to be determined whether the different reactivity between SFN and TNBS represents 
general difference between antioxidants and skin sensitizers.  Nevertheless, majority of skin 
sensitizers are sulfhydryl reactive agents [10, 13]. 
 
The significance of the induction of CES1 through the Nrf2 pathway remains to be determined.  
Carboxylesterases are generally considered detoxification enzymes, therefore, induction of 
CES1 likely represents cytoprotective response [1. 5].  On the other hand, induction of CES1 
may have pharmacological significance, particularly regarding the metabolism of ester drugs.  
For example, the antiplatelet agent clopidogrel undergoes predominant hydrolysis (95%) and 
hydrolysis represents inactivation [2].  As a result, exposure to antioxidants or skin sensitizers 
may decrease the antiplatelet activity of clopidogrel.  In contrast, hydrolysis of oseltamivir, a 
widely used anti-influenza agent, represents activation, and only the hydrolytic metabolite exerts 
anti-influenza activity [24].  Therefore, induction of CES1 likely leads to increased anti-viral 
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activity of oseltamivir.  We have shown that the hydrolytic metabolite, compared with the parent 
compound oseltamivir, is more cytotoxic [24].  However, the Nrf2-mediated induction of CES1 
may cause little changes in the overall toxicity as this pathway has also been found to support 
the induction of multidrug resistance protein-4 [25], a transporter that effluxes the hydrolytic 
metabolite [26]. 
 
In addition to the pharmacological implications, induction of CES1 may have pathophysiological 
significance as well.  CES1 hydrolyzes many endogenous compounds such as triglycerides and 
cholesterol esters [1, 4, 5].  Hydrolysis of cholesterol esters increases free cholesterol, leading 
to increased synthesis of bile acids [4].  Secretion of bile acids represents the only net 
elimination of excessive cholesterol [27].  On the other hand, increased free fatty acids by 
hydrolyzing triglycerides and cholesterol esters likely increase the synthesis and secretion of 
very low density lipoprotein (VLDL), a precursor that leads to the formation of low density 
lipoprotein (LDL) (28-30).  Indeed, high CES1 activity has been shown to facilitate VLDL 
maturation [29].  Transgenic expression of CES1 leads to increased secretion of apoB proteins 
and plasma triglycerides [28].  Elevated level of LDL increases the risk of developing 
atherosclerosis [31].  Therefore, excessive induction of CES1 without enhancing bile acid 
synthesis likely has detrimental effect. 
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INNOVATION 
Nuclear translocation of Nrf2 is the essential event in the activation of the Keap1-Nrf2 pathway 
[32-34].  Normally, Nrf2 is sequestered in the cytoplasm by complexing with Keap1.  The 
presence of antioxidants or sensitizers induce conformational changes of Keap1, leading to the 
release and nuclear translocation of Nrf2.  In this study, we have shown that both antioxidant 
and sensitizer activated this pathway but differed in inducing conformational changes of Keap1.  
SFN promoted the formation of intramolecular disulfide bonds whereas TNBS promoted the 
formation of intramolecular disulfide bonds of Keap1.  Another innovative finding of this study is 
the identification of ARE4 to support Nrf2 repression, given the fact that Nrf2 is generally 
considered to confer transactivation activity.  Interestingly, Nrf1, commonly referred as to 
functionally related to Nrf2 [17], exhibited opposite activity toward the ARE4 reporter, pointing to 
an important difference in their molecular recognition.  Finally, we have shown that the S/ARE 
element was activated the most among several well-established Nrf2 elements.   
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MATERIALS AND METHODS 
Hanks balanced salt solution, TNBS and William’s medium E (WME) were purchased from 
Sigma (St. Louis, MO).  SFN was purchased from Alexis (San Diego, CA).  Dulbecco’s Modified 
Eagles Medium (DMEM), high fidelity Platinum Taq DNA polymerase, insulin-transferrin-
selenium (ITS) G supplement were purchased from Invitrogen (Carlsbad, CA).  Dual-Luciferase 
Reporter Assay System was from Promega (Madison, WI).  Fetal bovine serum (FBS) was from 
HyClone laboratories (Logan, UT).  The antibody against glyceradehyde-3-phosphate dehydro-
genase (GAPDH) was from Abcam (Cambridge, UK), and the antibody against Nrf2 (C-20) was 
from Santa Cruz Biotechnology (Santa Cruz, CA).  The goat anti-rabbit IgG conjugated with 
horseradish peroxidase was from Pierce (Rockford, IL).  Plated human primary hepatocytes 
were obtained from the Liver Tissues Procurement and Distribution System (University of 
Minnesota) or CellzDirect (Pittsboro, NC).  Human dermal fibroblasts (cryopreserved) were 
purchased from Cascade Biologics (Portland, OR).  Unless otherwise specified, all other 
reagents were purchased from Fisher Scientific (Fair Lawn, NJ).  
  
Reporter constructs and cotransfection assays 
CES1A1 promoter reporters were prepared to contain various lengths of CES1A1 genomic 
sequence.  All promoter reporters were subcloned from the CES1A1-6560-Luc reporter.  This 
reporter was prepared by inserting the genomic fragment from -6560 to -21 (relatively to the 
translation initiation codon) into the pGL3 basic vector through Mlu I and Xho I sites.  All cloning 
and subcloning were performed by PCR with high fidelity Platinum Taq DNA polymerase.  To 
prepare the CES1A1-3582m-Luc reporter, site-directed mutagenesis was performed as 
described previously [35].  Complementary oligonucleotides (5’-CTCACCCATCACAATGTAC-
TGAGGAATCATGAAGCAGAAA-3’) were synthesized to introduce substitutions (underlined).  
The primers were annealed to the CES1A1-3582-Luc reporter and subjected to a thermocycler 
for a total of 15 cycles.  The resultant PCR-amplified constructs were then digested with Dpn I to 
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remove the non-mutated parent construct.  The mutated PCR-amplified constructs were used to 
transform XL1-Blue bacteria.  To prepare element reporters, oligonucleotides (Table I) were 
synthesized, annealed and ligated into the pGL3 promoter vector through Nhe I and Xho I.  All 
reporter constructs were subjected to sequence analysis.  To determine the reporter activities, 
cotransfection in Huh7 cells was performed.  Transfection mixtures contained 100 ng of a 
reporter plasmid and 0.2 ng of CMV-Renilla luciferase plasmid.  In some cases, Nrf1 and Nrf2 
constructs were included.  Nrf1 construct was a gift of Dr. Jefferson Y. Chan of University of 
California Irvine whereas Nrf2 construct was purchased from OriGene (Rockville, MD).  The 
corresponding vector was used to equalize the total amount of plasmid DNA.  Typically, cells 
were transfected for 12 h and the medium was replaced with fresh medium supplemented with 
1% FBS.  The treatment lasted for 24 h and the cells were washed once with phosphate 
buffered saline and collected by scraping.  The reporter enzyme activities were assayed with a 
Dual-Luciferase Reporter Assay System as described previously.   
 
Electrophoretic mobility shift assay (EMSA) 
The EMSA experiment was performed as described previously [36].    Nuclear extracts of Huh7 
cells treated with SFN (10 M) for 24 h were prepared with the nuclear and cytoplasmic 
extraction kit (Pierce, Rockford, IL).  The sense and antisense oligonucleotides (Table I) were 
annealed by heating at 94°C for 5 min followed by gradually cooling to room temperature.  The 
sense strand was synthesized as labeled or non-labeled form (for competition).  Nuclear protein 
(5 μg) was incubated with a double-stranded biotinylated probe (0.1 pmol) at room temperature 
for 20 min.  In competition assays, nuclear extracts were first incubated with an unlabeled probe 
at a 25x or 100x excess for 5 min before addition of the labeled probe.  For antibody-disruption 
assay, the nuclear extracts were first incubated with an antibody against Nrf2 (C-20) on ice for 
20 min and then with the labeled probe.  The protein-DNA complexes were resolved by non-
denaturing polyacrylamide gel electrophoresis (5%) and transferred onto a Biodyne® nylon 
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membrane.  The biotinylated probe was detected with streptavidin-conjugated horseradish 
peroxidase and chemiluminescent substrate (PIERCE, Rockford, IL).  The chemiluminescent 
signal was captured by KODAK Image Station 2000, and the relative intensities were quantified 
by KODAK 1D Image Analysis Software (KODAK Molecular Imaging Software, Version 4.0, 
Rochester, NY). 
 
Chromatin immunoprecipitation (ChIP)  
ChIP experiment was performed, essentially described previously [36, 37].  Huh7 Cells were 
treated with SFN (10 µM) for 24 h, washed and underwent cross-linking for 15 min by 1.0% 
formaldehyde at room temperature, and the cross-linking was terminated with glycine (final 
concentration of 125 mM).  The soluble chromatins were prepared as described previously [36].  
For ChIP experiment, chromatins were pre-cleared for 2 h at 4°C with protein G beads pre-
treated with herring sperm DNA (0.2 mg/ml) and BSA (0.5 mg/ml).  A fraction of the pre-cleared 
chromatins was stored at -80°C for later use as an input.  An antibody against Nrf2 was added 
into the pre-cleared chromatins, and an overnight incubation at 4°C was performed.  As a 
negative control, incubation was performed with pre-immune IgG. The antibody-bound 
chromatins and DNA input were analyzed by PCR for the presence of the genomic fragments 
containing the Nrf2-bound element with primers shown in Table I.  The PCR was performed with 
Platinum Taq DNA polymerase for a total of 32 cycles at 94C for 30 s, 58C for 30 s and 68C 
for 60 s.  A 3-min initial denaturation was performed.    
 
Other analyses Protein concentrations were determined with BCA assay (Pierce) based on 
albumin standard.  Western analysis and the preparation of anti-CES1 antibody were described 
elsewhere (37-39).  RT-qPCR with Taqman probes was performed as described previously [40].  
The Taqman probe identification numbers were: Hs00275607_m1 for CES1, Hs00168547_m1 
for NAD(P)H:quinine oxidoreductase 1 (NQO1), 4352934E for GAPDH and Hs00172187_m1 for 
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RNA polymerase II.  Data are presented as mean  SD of at least three separate experiments, 
except where results of blots are shown in which case a representative experiment is depicted 
in the figures.  All data were analyzed for statistical significance with PASW Statistics 18.  
Significant differences were made according to One-way ANOVA followed by a DUNCAN’s 
multiple comparison test (p < 0.05).  Bars assigned different letters indicate statistical 
significance among data-points.   
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Table I Sequences of Oligonucleotides 
 
Oligonucleotide    Sequence 
 
Native promoter reporters 
CES1A1-6560-MluI   5'-CTGCAACCTTCCCATCTCAGCTGTGACCCA-3’ 
CES1A1-6448-MluI   5'-AGCTAATGAATAGGATCTGGGTTTATAATC-3’ 
CES1A1-5017-MluI   5'-CAATACCCTAATTTCGATCTCTGAATGACC-3’ 
CES1A1-3582-MluI   5'-TATTGCTTACAGCTGAAGTG-3’ 
CES1A1-3432-MluI  5'-CAGGCAAAACCTAGGAGTGG-3’ 
CES1A1-2293-MluI   5'-TGATTAGAATATCTTCCTGATGTATAAAAG-3’ 
CES1A1-1426-MluI   5'-GATGTTTTCCAGCTTCATCCACGTTGTAGC-3’ 
CES1A1-3552-MluI   5'-GTTATATGTATTAAGCAAAA-3’ 
CES1A1-3532-MluI  5'-TTAGATCTATTGTAAGGCT-3’ 
CES1A1-3512-MluI   5'-TGGTAGGCTCCAGCCTCACC-3’ 
CES1A1-3492-MluI   5'-CATCACAATCTGCAGAGTCA-3’ 
CES1A1-3482-MluI   5'-TGCAGAGTCATCATGAAGCA-3’ 
CES1A1-10484XhoI 5’-ATACACTCGAGTCGGGGCCTGCGAGGTCTCTGTGCA-
GTTCA-3’ 
Element reporters 
CES1A1-S/ARE      5’-CACAATCTGCAGAGTCATCATGAAG-3’ 
CES1A1-ARE4  5’-TTAAGATCGTGAGACAGCATTAATC-3’  
CES1A2-S/ARE  5’-CACAATCTGCAGAATCATCATGAAC-3’ 
AKR1C2-ARE   5’-TTGATGCAGTCAGGGTGACTCAGCAGCT-3 
GCLM-ARE   5’-GAAGACAATGACTAAGCAGAAATC-3’ 
GCLC-ARE    5’-CCTCCCCGTGACTCAGCGCTTTGT-3'   
NQO1-ARE   5’-AGTCACAGTGACTCAGCAGAATCT-3’ 
 
EMSA 
CES1A1-S/ARE      5’-CACAATCTGCAGAGTCATCATGAAG-3’ 
CES1A1-S/ARE(mutant)    5’-CACAATGTACTGAGGAATCATGAAG-3’ 
CES1A1-ARE4  5’-TTAAGATCGTGAGACAGCATTAATC-3’ 
 
ChIP 
P1    5’- TATTGCTAGCCTGAAGTGTTGCAGGGGAGTT-3’ 
P2    5’- ACACCTCGAGCTGGCTCTTGGCCTATGAAGA-3’ 
P3    5’- ATAAGCTAGCTGAGTTGAGCCTATGTATTAG-3’ 
P4    5’- CATTCTCGAGTCCTGGCTGTAATCTTGTCAG-3’ 
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LEGENDS FOR FIGURES 
Fig. 1. Induction of CES1 by SFN and TNBS in human dermal fibroblast, human primary 
hepatocyte, and skin sarcoma line HT1080 and hepatoma line Huh7 Cells were cultured in 
12-well plates and were treated with SFN (10 µM), TNBS (10 µg/ml) or DMSO for 24 h.  Total 
RNA was isolated and subjected to qRT-PCR analysis for the level of CES1 mRNA (A-D) by 
Taqman probes as described in the section of Materials and Methods.  The signals from each 
target were normalized based on the signal from GAPDH and polymerase II and expressed as 
mean  SD.  Four individual donors were tested on human dermal fibroblasts, five on human 
hepatocytes and three separate experiments were performed on cell lines.  The asterisk signs 
indicate statistical significance (P < 0.05) from DMSO-treated cells.  To determine the 
corresponding induction at the protein level, lysates (20 µg) from control and treated Huh7 cells 
were subjected to SDS-PAGE and transferred electrophoretically to Trans-Blot nitrocellulose 
membranes.  The immunoblots were blocked in 5% non-fat dry milk, incubated with the antibody 
against CES1 or GAPDH.  The blots were detected with chemiluminescent substrate (E).  
 
Fig. 2. Identification of sensitizing/antioxidant response element (A) Activation of CES1A1 
reporters by SFN, TNBS or Nrf2 Huh7 cells in 48 well-plates were transiently transfected by 
GenJet version II.  For the SFN and TNBS treatment experiment, the transfection mixture 
contained 50 ng of a reporter and 0.2 ng of the CMV-Renilla luciferase plasmid.  After 
incubation at 37C for 12 h, the transfected cells were treated with SFN (10 µM), TNBS (10 
µg/ml) or the same volume of DMSO for 24 h.  Luciferase activities were determined with a 
Dual-Luciferase Reporter Assay System and the reporter activity was expressed as fold of 
activation.  For the Nrf2 experiment, the transfection mixture contained 50 ng of a reporter and 
0.2 ng of the CMV-Renilla luciferase plasmid, along with 10 ng Nrf2 expression construct or the 
corresponding vector.  (B) Identification of CES1A1 Nrf2 response element To further narrow 
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down the sequence that supports the responsiveness to Nrf2, the CES1A1-3582-Luc was 
further shortened from the 5’ end by 20 or 10 bases, and cotransfection was then performed as 
described above.  Data were collected from three independent experiments.  
 
Fig. 3. Analyses of the S/ARE element by EMSA and ChIP (A) EMSA analysis Nuclear 
extracts (5 μg) from Huh7 cells treated with SFN (10 µM) were incubated with a biotinylated 
probe containing the S/ARE element (0.1 pmol) for 20 min.  In the competition assay, nuclear 
extracts were pre-incubated with the unlabeled S/ARE element, S/ARE mutant or ARE4 at 25x 
or 100x excess for 5 min, and then incubated with the biotinylated probe.  In disruption assay, 
nuclear extracts were incubated first with an antibody against Nrf2 on ice for 20 min and then 
with the biotinylated probe.  The protein-DNA complexes were electrophoretically resolved and 
transferred to a Biodyne® nylon membrane.  The biotinylated probe was located with 
streptavidin-conjugated horseradish peroxidase and chemiluminescent substrate.  (B) ChIP 
analysis Huh7 Cells were treated with SFN (10 µM) for 24 h, washed and underwent cross-
linking for 15 min by 1% formaldehyde, and the cross-linking was terminated with 125 mM 
glycine.  The soluble chromatins were prepared, pre-cleared with protein G beads and 
incubated with anti-Nrf2 antibody or pre-immune IgG.  The antibody-bound chromatins and DNA 
input (1/20 of the antibody-bound chromatins) were analyzed by PCR for the presence of the 
genomic fragments containing the Nrf2-bound element with the primers indicated in the diagram.   
The primer sequences are shown in Table I. 
 
Fig. 4. Functional characterization of the S/ARE element (A) Activation of S/ARE containing 
or disrupting reporter by SFN Huh7 cells were transiently transfected by a reporter (50 ng) of the 
S/ARE-Luc, CEA1A1-3582-Luc or its mutant CES1A1-3582m-Luc along with 0.2 ng of the 
CMV-Renilla luciferase plasmid.  After incubation at 37C for 12 h, the transfected cells were 
treated with SFN (0-10 µM) or the same volume of DMSO for 24 h.  Luciferase activities were 
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determined and the reporter activity was expressed as fold of activation.  (B) Activation of 
S/ARE containing or disrupting reporter by TNBS Huh7 cells were transiently transfected as 
described above but treated with TNBS (0-10 µg/ml).  Likewise, the reporter activities were 
determined.  (B) Activation of S/ARE containing or disrupting reporter by Nrf2 Huh7 cells were 
transiently transfected with 50 ng reporter and 0.2 ng of the CMV-Renilla luciferase plasmid 
along with 0-20 ng Nrf2 expression construct.  The corresponding vector was used to equalize 
the amount of total plasmid.  The luciferase activities were determined 24 after the transfection. 
*Statistically significant from the controls.  
 
Fig. 5. Differential activation of various ARE reporters by Nrf1 and Nrf2 Huh7 cells were 
transiently transfected by a reporter (50 ng) and the CMV-Renilla luciferase plasmid (0.2 ng) 
along with 10 ng Nrf1, Nrf2 or the vector.  The luciferase activities were determined 24 h after 
the transfection.  The core-Nrf2 sequence from known Nrf2 target genes is shown in H.   
 
Fig. 6. Diagrammatical presentation of regulated transcription of the CES1A1 through the 
S/ARE and ARE4 elements The relative width of the arrows between Nrf2 to small Maf and 
Nrf2 to YY1 suggests the dominance of the formation of Nrf2-Maf dimmers over that of Nrf2-
YY1 dimers.  The double ended arrow between the Nrf2-YY1 dimers and the YY1-Nrf2 
composite element suggests weak interaction.  The dotted lines indicate possible direct 
interactions.        
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Fig. 1. Yan  (2011) 
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Fig. 2. Yan (2011) 
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Fig. 3, Yan (2011) 
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Fig. 4, Yan (2011) 
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Fig. 5, Yan (2011) 
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A: Oxidized intramolecular keap1; B: Reduced keap1; C: Oxidized intermolecular keap1; DMSO: 
Dimethyl sulfoxide; ME: 2-mercaptoethanol; SFN: sulforaphane; TNBS: trinitrobenzene sulfonate 
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Fig. 1. Reactivity of mouse and human Keap1 toward sulforaphane and trini-
trobenzene sulfonate  
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Fig. 6, Yan (2011) 
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